Mounjaro Consultation

Frequently Asked Questions

1. What is Mounjaro?

Mounjaro® contains tirzepatide, a medicine that helps regulate appetite, reduce food intake, and increase feelings of fullness to support weight management.

2. Who may be eligible for Mounjaro?

Mounjaro may be suitable for adults with obesity (BMI 30 or above), or those who are overweight (BMI 27 or above) with a weight-related health condition. Eligibility is determined during a consultation.

3. How does Mounjaro work?

Mounjaro works by activating GIP and GLP-1 receptors, helping reduce appetite, slow stomach emptying, and improve feelings of fullness.

4. How often is Mounjaro taken?

Mounjaro is administered as a once-weekly injection. Treatment typically starts at a lower dose and is increased gradually over time.

5. What are the common side effects?

Common side effects may include nausea, diarrhoea, constipation, vomiting, stomach discomfort, and reduced appetite. These effects are often more noticeable when starting treatment and may improve over time.

6. Is Mounjaro funded in New Zealand?

No. Mounjaro is currently not publicly funded in New Zealand and is available through private prescription or eligible pharmacy prescribing services.

7. How much weight can I expect to lose?

Results vary between individuals. Clinical studies have shown average weight loss of up to approximately 22.5% of body weight when Mounjaro is combined with ongoing lifestyle changes.

8. Will I need follow-up appointments?

Yes. Regular follow-up appointments are recommended to monitor progress, review side effects, adjust treatment where necessary, and support long-term success.